Vascular Biogenics Ltd. - Ordinary Shares (VBLT): Price and Financial Metrics


Vascular Biogenics Ltd. - Ordinary Shares (VBLT): $1.36

-0.16 (-10.53%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VBLT POWR Grades


  • Sentiment is the dimension where VBLT ranks best; there it ranks ahead of 93.72% of US stocks.
  • VBLT's strongest trending metric is Growth; it's been moving down over the last 161 days.
  • VBLT's current lowest rank is in the Momentum metric (where it is better than 4.06% of US stocks).

VBLT Stock Summary

  • Vascular Biogenics Ltd's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 7.43% of US listed stocks.
  • With a price/sales ratio of 124.9, Vascular Biogenics Ltd has a higher such ratio than 97.65% of stocks in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for VBLT comes in at -36.23% -- higher than that of only 10.81% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Vascular Biogenics Ltd are SYBX, AYLA, ALT, GNCA, and ARDS.
  • VBLT's SEC filings can be seen here. And to visit Vascular Biogenics Ltd's official web site, go to www.vblrx.com.

VBLT Valuation Summary

  • VBLT's price/sales ratio is 186.4; this is 1542.29% higher than that of the median Healthcare stock.
  • VBLT's price/sales ratio has moved NA NA over the prior 84 months.
  • VBLT's EV/EBIT ratio has moved up 3.9 over the prior 84 months.

Below are key valuation metrics over time for VBLT.

Stock Date P/S P/B P/E EV/EBIT
VBLT 2021-08-31 186.4 2.6 -5.3 -4.2
VBLT 2021-08-30 170.4 2.4 -4.8 -3.7
VBLT 2021-08-27 166.5 2.4 -4.7 -3.6
VBLT 2021-08-26 161.0 2.3 -4.5 -3.5
VBLT 2021-08-25 160.2 2.3 -4.5 -3.5
VBLT 2021-08-24 161.0 2.3 -4.5 -3.5

VBLT Growth Metrics

    Its 4 year net income to common stockholders growth rate is now at -23.97%.
  • Its 4 year net cashflow from operations growth rate is now at -3.84%.
  • The 5 year net cashflow from operations growth rate now stands at -3.84%.
VBLT's revenue has moved up $136,000 over the prior 30 months.

The table below shows VBLT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 0.777 -25.545 -28.07
2021-06-30 0.771 -22.289 -27.345
2021-03-31 0.741 -23.552 -25.155
2020-12-31 0.922 -23.378 -24.225
2020-09-30 0.843 -19.831 -22.697
2020-06-30 0.729 -19.999 -21.776

VBLT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VBLT has a Quality Grade of C, ranking ahead of 42.6% of graded US stocks.
  • VBLT's asset turnover comes in at 0.015 -- ranking 380th of 682 Pharmaceutical Products stocks.
  • ISEE, SRNE, and CNCE are the stocks whose asset turnover ratios are most correlated with VBLT.

The table below shows VBLT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.015 0.403 -1.059
2021-03-31 0.016 0.418 -0.951
2020-12-31 0.020 0.573 -0.863
2020-09-30 0.018 0.724 -0.741
2020-06-30 0.015 0.742 -0.740
2020-03-31 0.014 0.749 -0.628

VBLT Price Target

For more insight on analysts targets of VBLT, see our VBLT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.38 Average Broker Recommendation 1.38 (Strong Buy)

VBLT Stock Price Chart Interactive Chart >

Price chart for VBLT

VBLT Price/Volume Stats

Current price $1.36 52-week high $3.17
Prev. close $1.52 52-week low $1.35
Day low $1.35 Volume 868,619
Day high $1.56 Avg. volume 298,640
50-day MA $2.05 Dividend yield N/A
200-day MA $2.17 Market Cap 84.82M

Vascular Biogenics Ltd. - Ordinary Shares (VBLT) Company Bio


Vascular Biogenics Limited is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases. The company was founded in 2000 and is based in Or Yehuda, Israel.


VBLT Latest News Stream


Event/Time News Detail
Loading, please wait...

VBLT Latest Social Stream


Loading social stream, please wait...

View Full VBLT Social Stream

Latest VBLT News From Around the Web

Below are the latest news stories about Vascular Biogenics Ltd that investors may wish to consider to help them evaluate VBLT as an investment opportunity.

VBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial Officer

CCO appointment positions VBL to advance and accelerate commercialization strategy for ofra-vec (VB-111) Enrollment in the OVAL Study, a 400 patient Phase 3 registration-enabling trial in ovarian cancer, expected to be completed this quarter; PFS co-primary endpoint readout expected in 2H22 has potential to support BLA filing TEL AVIV, Israel and NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class ther

Yahoo | January 18, 2022

VBL Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference

TEL AVIV, Israel and NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune-inflammatory indications, today announced that Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will present a corporate overview at the H.C. Wainwright BioConnect Virtual Conference being held on January 10 – 13, 2022. H.C. Wainwright BioConnect Virtu

Yahoo | January 6, 2022

BridgeBio (BBIO) Tumbles on Cardiomyopathy Candidate Failure

BridgeBio's (BBIO) acoramidis fails to meet the primary endpoint of a six-minute walk test in cardiomyopathy patients. However, secondary data demonstrate a favorable trend. The study continues.

Yahoo | December 28, 2021

VBL Therapeutics Selected for €17.5 Million of Funding from Horizon Europe EIC Accelerator Program

VBL is among only 9% of companies across industries selected by the EIC Accelerator Funds to be used for clinical development, CMC, and pre-commercialization activities for ofra-vec (VB-111) TEL AVIV, Israel and NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that it has been selected for €

Yahoo | December 20, 2021

Reata (RETA) Falls on Negative Advisory Committee Outcome

An FDA advisory committee believes Reata's (RETA) bardoxolone study data does not support the effectiveness of the candidate in slowing the progression of CKD in patients with Alport syndrome.

Yahoo | December 9, 2021

Read More 'VBLT' Stories Here

VBLT Price Returns

1-mo -34.30%
3-mo -42.13%
6-mo -39.82%
1-year -45.60%
3-year 18.26%
5-year -73.07%
YTD -30.96%
2021 4.23%
2020 57.50%
2019 23.71%
2018 -86.34%
2017 46.39%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8194 seconds.